Respiratory therapy

Viemed Healthcare Announces Date and Time for Conference Call

Retrieved on: 
Wednesday, February 26, 2020

To pre-register as a qualified caller, please e-mail [email protected] by 12:00 p.m. EST Monday, March 2, 2020.

Key Points: 
  • To pre-register as a qualified caller, please e-mail [email protected] by 12:00 p.m. EST Monday, March 2, 2020.
  • Viemed, through its indirect wholly-owned subsidiaries Sleep Management, L.L.C.
  • and Home Sleep Delivered, L.L.C., is a home medical equipment supplier that provides post-acute respiratory care services in the United States.
  • focuses on disease management and improving the quality of life for respiratory patients through clinical excellence, education, and technology.

Masimo and MS Westfalia GmbH (MSW) Expand Partnership to Add Masimo SedLine® Brain Function Monitoring, O3® Regional Oximetry, and Oxygen Reserve Index (ORi™) to the MSW Modular Point-of-Care Hybrid Jenny

Retrieved on: 
Tuesday, February 25, 2020

Masimo (NASDAQ: MASI) and MS Westfalia GmbH (MSW) announced today that MSW will integrate additional Masimo measurement technologies into MSWs plug-and-play hybrid Jenny platform, to help clinicians assess brain function, oxygenation, ventilation, and resuscitation status.

Key Points: 
  • Masimo (NASDAQ: MASI) and MS Westfalia GmbH (MSW) announced today that MSW will integrate additional Masimo measurement technologies into MSWs plug-and-play hybrid Jenny platform, to help clinicians assess brain function, oxygenation, ventilation, and resuscitation status.
  • O3 Regional Oximetry, which may help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.
  • ORi, the first noninvasive and continuous parameter to provide insight into the oxygen reserve of patients receiving supplemental oxygen.
  • Eugen Kagan, CEO of MSW, said, Our companys mission is to save lives and improve quality of life for our patients.

Oxygen Industry Insights, Worldwide, 2015-2030

Retrieved on: 
Monday, February 24, 2020

Increasing prevalence of various diseases related to breathing problems contributed to the global Oxygen market's growth by increasing use of Oxygen for medical purposes.

Key Points: 
  • Increasing prevalence of various diseases related to breathing problems contributed to the global Oxygen market's growth by increasing use of Oxygen for medical purposes.
  • Thus, the increased number of such cases has surged the demand for portable oxygen concentrators, therefore driving the Oxygen market's growth.
  • Therefore, lack of safety measures while handling Oxygen negatively affecting the Oxygen market.
  • All the three acquired companies are involved in oxygen-related product business including oxygen concentrators, liquid oxygen systems and oxygen generation systems used in hospitals and other institutions as their prime business.

Global Oxygen Therapy Equipment Market Forecast to Grow to US$3.5 Billion by 2025

Retrieved on: 
Monday, February 24, 2020

DUBLIN, Feb. 24, 2020 /PRNewswire/ -- The "Oxygen Therapy Equipment - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 24, 2020 /PRNewswire/ -- The "Oxygen Therapy Equipment - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The Oxygen Therapy Equipment market worldwide is projected to grow by US$2.1 Billion, driven by a compounded growth of 8.3%.
  • Oxygen Source, one of the segments analyzed and sized in this study, displays the potential to grow at over 8.7%.
  • Poised to reach over US$3.5 Billion by the year 2025, Oxygen Source will bring in healthy gains adding significant momentum to global growth.

Teva Announces FDA Approval of ArmonAir® Digihaler™ (fluticasone propionate) Inhalation Powder

Retrieved on: 
Monday, February 24, 2020

Patients also can schedule reminders on their smartphone to take either their ArmonAir Digihaler or AirDuo Digihaler as prescribed.

Key Points: 
  • Patients also can schedule reminders on their smartphone to take either their ArmonAir Digihaler or AirDuo Digihaler as prescribed.
  • The approval of ArmonAir Digihaler is based on the review of the supplemental new drug application (sNDA) submitted by Teva to the FDA.
  • ArmonAir Digihaler was approved in a low, medium and high dose: 55 mcg, 113 mcg and 232 mcg administered as one inhalation twice daily.
  • ArmonAir Digihaler (fluticasone propionate) inhalation powder is a prescription inhaled corticosteroid (ICS) medicine for the long-term treatment of asthma in patients 12 years and older.

Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update

Retrieved on: 
Friday, February 21, 2020

LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the full year ended December 31, 2019 on Thursday, February 27, 2020 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss the full year financial results and provide a corporate update.

Key Points: 
  • LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the full year ended December 31, 2019 on Thursday, February 27, 2020 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss the full year financial results and provide a corporate update.
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • Verona Pharma is currently in Phase 2 development with three formulations of ensifentrine for the treatment of COPD: nebulized, dry powder inhaler, and pressurized metered-dose inhaler.
  • Ensifentrine also has potential applications in cystic fibrosis, asthma and other respiratory diseases.

Global Disposable Respiratory Masks Market 2019-2023 | Evolving Opportunities with 3M and Ambu | Technavio

Retrieved on: 
Thursday, February 20, 2020
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200220005542/en/
    Technavio has announced its latest market research report titled Global Disposable Respiratory Masks Market 2019-2023 (Graphic: Business Wire)
    Read the 107-page report with TOC on Disposable Respiratory Masks Market Analysis Report by Product (LMA and Face mask), Geography (Americas, APAC, and EMEA), and the Segment Forecasts, 2019-2023.
  • In addition, the shift toward disposable devices in developed countries is anticipated to boost the growth of the disposable respiratory masks market.
  • Request a free sample report
    Related Reports on Healthcare are:
    Global Disposable Oxygen Masks Market Global disposable oxygen masks market by product (adult-size disposable oxygen masks and pediatric-size disposable oxygen masks) and geography (Asia, Europe, North America, and ROW).
  • Global Anesthetic Gas Masks Market Global anesthetic gas masks market by product (disposable anesthetic gas masks and reusable anesthetic gas masks) and geography (Asia, Europe, North America, and ROW).

InventHelp Presents Retractable Oxygen Hose Holder (KOC-1117)

Retrieved on: 
Thursday, February 20, 2020

PITTSBURGH, Feb. 20, 2020 /PRNewswire/ -- Until now patients requiring constant access to oxygen via an oxygen concentrator, had to leave their oxygen hose lying on the floor.

Key Points: 
  • PITTSBURGH, Feb. 20, 2020 /PRNewswire/ -- Until now patients requiring constant access to oxygen via an oxygen concentrator, had to leave their oxygen hose lying on the floor.
  • He developed OXYGEN HOSE REEL to afford users greater independence and mobility since it keeps the hose from snagging and tangling.
  • As such, it reduces expense for replacement of damaged hose lines and prevents the hose from becoming a trip hazard.
  • "I am tethered to an oxygen concentrator 24/7," he said, "and have to gather up my hose to go anywhere."

InventHelp Presents Protector for Nasal Cannula (SOG-354)

Retrieved on: 
Wednesday, February 19, 2020

PITTSBURGH, Feb. 19, 2020 /PRNewswire/ -- "I use oxygen and found a need for a way to protect the nasal ports of my cannula from contamination," said an inventor from Rio Vista, Calif. "That inspired me to invent this handy and convenient protector."

Key Points: 
  • PITTSBURGH, Feb. 19, 2020 /PRNewswire/ -- "I use oxygen and found a need for a way to protect the nasal ports of my cannula from contamination," said an inventor from Rio Vista, Calif. "That inspired me to invent this handy and convenient protector."
  • She developed the OXYGEN CANNULA PROTECTOR, patent pending, to protect a nasal cannula and keeps the nostril ports clean and hygienic.
  • The original design was submitted to the San Diego sales office of InventHelp.
  • 18-SOG-354, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

The North America high-flow nasal cannula market is expected to reach US$ 4,261.14 Mn in 2027 from US$ 1,644.50 Mn in 2018

Retrieved on: 
Tuesday, February 18, 2020

The North America high-flow nasal cannula market is expected to reach US$ 4,261.14 Mn in 2027 from US$ 1,644.50 Mn in 2018.

Key Points: 
  • The North America high-flow nasal cannula market is expected to reach US$ 4,261.14 Mn in 2027 from US$ 1,644.50 Mn in 2018.
  • However, adverse effects or risk of high flow nasal cannula is likely to have a negative impact on the growth of the market in the coming years.
  • In 2018, the US high-flow nasal cannula market held the largest share of the North America high-flow nasal cannula market because it has highest COPD prevalence.
  • Chronic Obstructive Pulmonary Disease segment a largest market share of the high-flow nasal cannula market, by application in 2018.